ACTRN12618001197224已完成不适用
A single dose, cross-over pharmacokinetic study comparing oral formulations of BNC210 in healthy male volunteers
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- Male
入选标准
- •1. Agree to and be capable of signing informed consent form.
- •2. Adult males aged 18-65 years (inclusive).
- •3. Body mass index within the range of 18-30 kg/m^2.
- •4. Good general health without clinically significant renal, hepatic, cardiac or respiratory disease, as determined by the Investigator.
- •5. Have suitable venous access for blood sampling.
- •6. Agree to abstain from sexual intercourse or use a highly effective method of birth control with partners of childbearing potential for the duration of the study and for 3 months after the last dose of study drug.
排除标准
- •1. Any medical condition that in the opinion of the Investigator may adversely impact on the participant’s ability to complete the study.
- •2. Renal impairment as evidenced by estimated creatinine clearance, measured by the Cockcroft-Gault method of less than 90 mL/min.
- •3. Have a laboratory value at the Screening Visit that is outside the normal range, unless it is judged by the Investigator as not clinically significant after appropriate evaluation.
- •4. Plasma AST (aspartate transaminase), ALT (alanine transaminase), and ALP (alkaline phosphatase) tests in excess of 1.5 times the upper limit of normal.
- •5. History of severe allergic or anaphylactic drug-related reactions.
- •6. Known past or present mental health disorder.
- •7. Concurrent use of any prescription medication, over the counter medication or complementary / alternative medication within 2 weeks prior to dosing (single or multiple doses).
- •8. Consumption of grapefruit, grapefruit juice, red wine or St. John’s Wort within 2 weeks prior to first dose.
- •9. Participation in another clinical trial of an investigational agent within 30 days of study entry.
- •10. Known history of past or present infection with hepatitis C virus (HCV), hepatitis B (HBV) or human immunodeficiency virus (HIV).
- •11. Clinically significant abnormal ECG (12-lead) at the Screening Visit as determined by the Investigator.
- •12. Participants who have a marked prolongation of the QTcF corrected interval (i.e., repeated demonstration of a QTcF interval >460 msec for females or >440 msec for males) at Screening.
- •13. Significant history of illicit drug or alcohol use or abuse (as determined by the Investigator) within 1 year of the Screening Visit.
- •14. Unwillingness or inability to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the participant returning for visits on schedule.
- •15. Blood donation (1 unit or more) within 1 month prior to the Screening Visit.
- •16. Smoked cigarettes, tobacco and/or tetrahydrocannabinol containing products within 2 weeks prior to first dose.
研究者
相似试验
进行中（未招募）
不适用
A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sitagliptin in AdolescentsType 2 Diabetes MellitusEUCTR2014-004993-40-Outside-EU/EEAMerck & Co., Inc.35
进行中（未招募）
1 期
PK Study in Adolescents and Young Adults Treated with GlucocorticoidsMedDRA version: 18.1Level: PTClassification code 10031282Term: OsteoporosisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersOsteoporosisEUCTR2012-003414-14-GBMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (hereafter referred to as19
进行中（未招募）
不适用
PK Study in Adolescents with Glucocorticoid-Induced OsteoporosisosteoporosisEUCTR2012-003414-14-Outside-EU/EEAMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (hereafter referred to as16
进行中（未招募）
1 期
PK Study in Adolescents and Young Adults Treated with GlucocorticoidsOsteoporosisEUCTR2012-003414-14-ITMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.24
进行中（未招募）
1 期
PK Study in Adolescents and Young Adults Treated with GlucocorticoidsOsteoporosisMedDRA version: 18.1Level: PTClassification code 10031282Term: OsteoporosisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2012-003414-14-FIMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (hereafter referred to as19